









市场行情
/
股票
/
nasdaq-vnrx
/

VolitionRX Ltd

VNRX

0.262USD

-0.006-2.21%

收盘 12/19, 16:00（美东）报价延迟15分钟

28.67M总市值

亏损市盈率 TTM



VolitionRX Ltd

0.262

-0.006-2.21%

概览公司财务分析

概览

公司

财务

分析

关于 VolitionRX Ltd 公司

VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

VolitionRX Ltd简介



公司代码VNRX

公司名称VolitionRX Ltd

上市日期Feb 06, 2015

CEOButera (Salvatore Thomas)

员工数量85

证券类型Ordinary Share

年结日Feb 06

公司地址1489 West Warm Springs Road

城市HENDERSON

上市交易所NASDAQ OMX – NASDAQ Basic Amex

国家United States of America

邮编89014

电话17024251561

网址https://volition.com/

公司代码VNRX

上市日期Feb 06, 2015

CEOButera (Salvatore Thomas)

VolitionRX Ltd公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Guy Archibald Innes

Independent Director

2.98M

+3.33%

Mr. Cameron John Reynolds

President, Chief Executive Officer, Director

2.31M

+0.87%

Dr. Jacob Vincent Micallef

Chief Scientific Officer

444.76K

-1.30%

Mr. Terig Hughes

Chief Financial Officer, Treasurer

388.15K

+7.22%

Dr. Salvatore Thomas Butera

Chief Executive Officer of Volition Vet

325.40K

-1.41%

Dr. Jasmine Kway

Chief Executive Officer of Singapore Volition

203.61K

+6.54%

Dr. Alan Colman, Ph.D.

Independent Director

203.55K

-10.28%

Mr. Gael Forterre

Chief Commercial Officer

153.78K

-1.13%

Mr. Nicholas Plummer

Group General Counsel

150.58K

-3.61%

Dr. Andrew Retter

Chief Medical Officer

146.57K

-3.04%

名称

名称/职务

职务

持股

持股变动

Mr. Guy Archibald Innes

Independent Director

2.98M

+3.33%

Mr. Cameron John Reynolds

President, Chief Executive Officer, Director

2.31M

+0.87%

Dr. Jacob Vincent Micallef

Chief Scientific Officer

444.76K

-1.30%

Mr. Terig Hughes

Chief Financial Officer, Treasurer

388.15K

+7.22%

Dr. Salvatore Thomas Butera

Chief Executive Officer of Volition Vet

325.40K

-1.41%

Dr. Jasmine Kway

Chief Executive Officer of Singapore Volition

203.61K

+6.54%

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

Lagoda Investment Management, L.P.

10.17%

Cotterford Co., Ltd.

9.78%

Armistice Capital LLC

7.64%

Innes (Guy Archibald)

2.43%

Reynolds (Cameron John)

1.88%

其他

68.11%

持股股东

占比

Lagoda Investment Management, L.P.

10.17%

Cotterford Co., Ltd.

9.78%

Armistice Capital LLC

7.64%

Innes (Guy Archibald)

2.43%

Reynolds (Cameron John)

1.88%

其他

68.11%

股东类型

持股股东

占比

Investment Advisor

12.08%

Corporation

10.60%

Hedge Fund

8.00%

Individual Investor

6.56%

Investment Advisor/Hedge Fund

1.12%

Research Firm

0.04%

Venture Capital

0.03%

Bank and Trust

0.01%

其他

61.57%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

23.92M

20.70%

+1.72M

2025Q2

41.39M

40.30%

+860.69K

2025Q1

44.42M

46.85%

+2.70M

2024Q4

41.53M

44.82%

+1.50M

2024Q3

38.59M

41.90%

+9.42M

2024Q2

28.77M

32.86%

+105.49K

2024Q1

28.22M

34.52%

+1.47M

2023Q4

26.17M

37.10%

+183.39K

2023Q3

25.37M

36.48%

-477.38K

2023Q2

25.03M

37.36%

-1.92M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Lagoda Investment Management, L.P.

11.71M

10.88%

+1.51M

+14.82%

Jun 30, 2025

Cotterford Co., Ltd.

12.01M

11.16%

Apr 25, 2025

Armistice Capital LLC

8.49M

7.89%

+286.64K

+3.49%

Jun 30, 2025

Innes (Guy Archibald)

2.88M

2.68%

+78.13K

+2.78%

Aug 05, 2025

Reynolds (Cameron John)

2.18M

2.02%

+15.00K

+0.69%

Sep 12, 2025

The Vanguard Group, Inc.

1.62M

1.51%

+918.67K

+130.11%

Jun 30, 2025

Concord International Inc.

1.01M

0.94%

Apr 25, 2025

Geode Capital Management, L.L.C.

764.89K

0.71%

+2.94K

+0.39%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

445.19K

0.41%

Jun 30, 2025

Micallef (Jacob Vincent)

450.61K

0.42%

-5.57K

-1.22%

Sep 28, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Micro-Cap ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

VolitionRX Ltd的前五大股东是谁？



VolitionRX Ltd 的前五大股东如下：
Lagoda Investment Management, L.P.持有股份：11.71M，占总股份比例：10.88%。
Cotterford Co., Ltd.持有股份：12.01M，占总股份比例：11.16%。
Armistice Capital LLC持有股份：8.49M，占总股份比例：7.89%。
Innes (Guy Archibald)持有股份：2.88M，占总股份比例：2.68%。
Reynolds (Cameron John)持有股份：2.18M，占总股份比例：2.02%。